December 19th 2024
Using Orexo’s powder-based drug delivery technology, the companies will develop mucosal vaccines in an inhaled formulation.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
EXO Biologics and ExoXpert Reach Two Critical Milestones that Advance Exosomes
December 3rd 2024EXO Biologics and its subsidiary, ExoXpert, have received GMP certification of a European exosomes manufacturing facility and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.